• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    4/2/24 5:44:00 PM ET
    $GTH
    Medical Specialities
    Health Care
    Get the next $GTH alert in real time by email
    SC 13D/A 1 ea0203212-13da1vivo9_genet.htm AMENDMENT NO. 1 TO SCHEDULE 13D

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

     

     

     

    SCHEDULE 13D/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)*

     

     

     

    Genetron Holdings Limited
    (Name of Issuer)

     

    Ordinary share, par value $0.00002, represented by American Depositary Shares
    (Title of Class of Securities)

     

    37186H209
    (CUSIP Number)

     

    Frank Kung

    Vivo Capital LLC

    192 Lytton Avenue

    Palo Alto, CA 94301

    Telephone: (650) 688-0818
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    March 28, 2024
    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☒

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a Reporting Entity’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 37186H209

     

    (1)

    Names of Reporting Entities

     

    Vivo Capital IX, LLC

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ☐     (b) ☒

    (3)

    SEC USE ONLY

     

    (4)

    Source of funds (see instructions)

     

    AF

    (5)

    Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

    ☐
    (6)

    Citizenship or place of organization

     

    Delaware

    Number of shares beneficially owned by each reporting person with (7)

    Sole voting power

     

    0

    (8)

    Shared voting power

     

    0

    (9)

    Sole dispositive power

     

    0

    (10)

    Shared dispositive power

     

    0

    (11)

    Aggregate amount beneficially owned by each Reporting Entity

     

    0

    (12)

    Check box if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    ☐
    (13)

    Percent of class represented by amount in Row (11)

     

    0%

    (14)

    Type of Reporting Entity (see instructions)

     

    OO

     

    2

     

     

    CUSIP No. 37186H209

     

    (1)

    Names of Reporting Entities

     

    Vivo Capital Fund IX, L.P.

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ☐     (b) ☒

    (3)

    SEC USE ONLY

     

    (4)

    Source of funds (see instructions)

     

    WC

    (5)

    Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

    ☐
    (6)

    Citizenship or place of organization

     

    Delaware

    Number of shares beneficially owned by each reporting person with (7)

    Sole voting power

     

    0

    (8)

    Shared voting power

     

    0

    (9)

    Sole dispositive power

     

    0

    (10)

    Shared dispositive power

     

    0

    (11)

    Aggregate amount beneficially owned by each Reporting Entity

     

    0

    (12)

    Check box if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    ☐
    (13)

    Percent of class represented by amount in Row (11)

     

    0%

    (14)

    Type of Reporting Entity (see instructions)

     

    PN

     

    3

     

     

    CUSIP No. 37186H209

     

    (1)

    Names of Reporting Entities

     

    Vivo Opportunity, LLC

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ☐     (b) ☒

    (3)

    SEC USE ONLY

     

    (4)

    Source of funds (see instructions)

     

    AF

    (5)

    Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

    ☐
    (6)

    Citizenship or place of organization

     

    Delaware

    Number of shares beneficially owned by each reporting person with (7)

    Sole voting power

     

    0

    (8)

    Shared voting power

     

    0

    (9)

    Sole dispositive power

     

    0

    (10)

    Shared dispositive power

     

    0

    (11)

    Aggregate amount beneficially owned by each Reporting Entity

     

    0

    (12)

    Check box if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    ☐
    (13)

    Percent of class represented by amount in Row (11)

     

    0%

    (14)

    Type of Reporting Entity (see instructions)

     

    OO

     

    4

     

     

    CUSIP No. 37186H209

     

    (1)

    Names of Reporting Entities

     

    Vivo Opportunity Fund Holdings, L.P.

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ☐     (b) ☒

    (3)

    SEC USE ONLY

     

    (4)

    Source of funds (see instructions)

     

    WC

    (5)

    Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

    ☐
    (6)

    Citizenship or place of organization

     

    Delaware

    Number of shares beneficially owned by each reporting person with (7)

    Sole voting power

     

    0

    (8)

    Shared voting power

     

    0

    (9)

    Sole dispositive power

     

    0

    (10)

    Shared dispositive power

     

    0

    (11)

    Aggregate amount beneficially owned by each Reporting Entity

     

    0

    (12)

    Check box if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    ☐
    (13)

    Percent of class represented by amount in Row (11)

     

    0%

    (14)

    Type of Reporting Entity (see instructions)

     

    PN

     

    5

     

     

    CUSIP No. 37186H209

     

    (1)

    Names of Reporting Entities

     

    Vivo Asia Opportunity, LLC

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ☐     (b) ☒

    (3)

    SEC USE ONLY

     

    (4)

    Source of funds (see instructions)

     

    AF

    (5)

    Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

    ☐
    (6)

    Citizenship or place of organization

     

    Cayman Islands

    Number of shares beneficially owned by each reporting person with (7)

    Sole voting power

     

    0

    (8)

    Shared voting power

     

    0

    (9)

    Sole dispositive power

     

    0

    (10)

    Shared dispositive power

     

    0

    (11)

    Aggregate amount beneficially owned by each Reporting Entity

     

    0

    (12)

    Check box if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    ☐
    (13)

    Percent of class represented by amount in Row (11)

     

    0%

    (14)

    Type of Reporting Entity (see instructions)

     

    OO

     

    6

     

     

    CUSIP No. 37186H209

     

    (1)

    Names of Reporting Entities

     

    Vivo Asia Opportunity Fund Holdings, L.P.

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ☐     (b) ☒

    (3)

    SEC USE ONLY

     

    (4)

    Source of funds (see instructions)

     

    WC

    (5)

    Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

    ☐
    (6)

    Citizenship or place of organization

     

    Cayman Islands

    Number of shares beneficially owned by each reporting person with (7)

    Sole voting power

     

    0

    (8)

    Shared voting power

     

    0

    (9)

    Sole dispositive power

     

    0

    (10)

    Shared dispositive power

     

    0

    (11)

    Aggregate amount beneficially owned by each Reporting Entity

     

    0

    (12)

    Check box if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    ☐
    (13)

    Percent of class represented by amount in Row (11)

     

    0%

    (14)

    Type of Reporting Entity (see instructions)

     

    PN

     

    7

     

     

    Explanatory Note: This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) amends the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on October 19, 2023 (the “Original Schedule 13D”), which relates to the Ordinary Shares, par value $0.00002 (the “Ordinary Shares”), represented by American Depositary Shares (the “ADSs”), each of which represents fifteen Ordinary Shares, of Genetron Holdings Limited (the “Issuer” or the “Company”). Information reported in the Original Schedule 13D remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment No. 1. Capitalized terms used but not defined in this Amendment No. 1 have the respective meanings set forth in the Original Schedule 13D.

     

    8

     

     

    Item 4.Purpose of Transaction.

     

    On March 28, 2024, the Company and Merger Sub filed the Plan of Merger with the Registrar of Companies of the Cayman Islands, which was registered by the Registrar of Companies of the Cayman Islands as of March 28, 2024, pursuant to which the Merger became effective on March 28, 2024 (the “Effective Time”). As a result of the Merger, the Company became a wholly owned subsidiary of Parent.

     

    At the Effective Time, each Ordinary Share of the Issuer issued and outstanding immediately prior to the Effective Time, other than the Excluded Shares and the Dissenting Shares (each as defined in the Merger Agreement) and Ordinary Shares represented by ADSs, was cancelled and ceased to exist in exchange for the right to receive US$0.272 per Ordinary Share in cash, and each ADS issued and outstanding immediately prior to the Effective Time, other than ADSs representing the Excluded Shares, together with the Ordinary Shares represented by such ADSs, was cancelled and ceased to exist in exchange for the right to receive US$4.08 per ADS in cash.

     

    At the Effective Time, certain Shares of the Rollover Shareholders, including all Shares held by Vivo Capital Fund IX, L.P., were cancelled and ceased to exist for no cash consideration from the Issuer in exchange of certain equity interest of Parent.

     

    Item 5.Interest in Securities of the Issuer.

     

    (a)-(b) As a result of the Merger, as described in Item 4 of this Amendment No. 1, the Reporting Persons do not beneficially own any Ordinary Shares or ADSs, nor do they have any voting power or dispositive power over any Ordinary Shares or ADSs.

     

    (c) Except as set forth in Item 4 of this Amendment No. 1, none of the Reporting Persons has effected any transaction of the Issuer’s Ordinary Shares or ADSs in the last 60 days.

     

    (d) Not applicable.

     

    (e) At the Effective Time, each of the Reporting Persons ceased to be the beneficial owner of more than 5% of Ordinary Shares.

     

    9

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: April 2, 2024

     

    VIVO CAPITAL FUND IX, L.P.  
       
    By: Vivo Capital IX, LLC  
       
    /s/ Frank Kung  
    Name:  Frank Kung  
    Title: Managing Member  

     

    VIVO CAPITAL IX, LLC  
       
    /s/ Frank Kung  
    Name: Frank Kung  
    Title:

    Managing Member

     

     
    VIVO OPPORTUNITY FUND HOLDINGS, L.P,  
       
    By: Vivo Opportunity, LLC  
       
    /s/ Frank Kung  
    Name:  Frank Kung  
    Title: Managing Member  

     

    VIVO OPPORTUNITY, LLC  
       
    /s/ Frank Kung  
    Name: Frank Kung  
    Title: Managing Member  
    VIVO ASIA OPPORTUNITY FUND HOLDINGS, L.P.  
       
    By: Vivo Asia Opportunity, LLC  
       
    /s/ Frank Kung  
    Name:  Frank Kung  
    Title: Managing Member  

     

    VIVO ASIA OPPORTUNITY, LLC  
       
    /s/ Frank Kung  
    Name:  Frank Kung  
    Title: Managing Member  

     

     

    10

     

     

    Get the next $GTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GTH
    SEC Filings

    View All

    SEC Form 15-12G filed by Genetron Holdings Limited

    15-12G - Genetron Holdings Ltd (0001782594) (Filer)

    4/8/24 6:04:10 AM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form S-8 POS filed by Genetron Holdings Limited

    S-8 POS - Genetron Holdings Ltd (0001782594) (Filer)

    3/29/24 6:02:34 AM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form 25-NSE filed by Genetron Holdings Limited

    25-NSE - Genetron Holdings Ltd (0001782594) (Subject)

    3/28/24 4:24:30 PM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genetron Health Announces Completion of Going Private Transaction

    BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the "Merger") with Genetron New Co Limited ("Merger Sub"), pursuant to the previously announced agreement and plan of merger, dated as of October 11, 2023 (the "Merger Agreement"), among the Company, New Genetron Holding Limited ("Parent") and Merger Sub. As a result of the Merger, the Company has become a wholly owned subsidiary of Parent and wil

    3/28/24 1:30:11 PM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health Announces Shareholders' Approval of Merger Agreement

    BEIJING, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that at an extraordinary general meeting of shareholders (the "EGM") held today, the Company's shareholders voted in favor of, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of October 11, 2023 (the "Merger Agreement"), among the Company, New Genetron Holding Limited ("Parent") and Genetron New Co Limite

    2/21/24 6:00:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health to Hold Extraordinary General Meeting of Shareholders

    BEIJING, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has called an extraordinary general meeting of shareholders (the "EGM"), to be held at on February 21, 2024 at 9:00 a.m. (Beijing time) at 1/F, Building 11, Zone 1, No. 8 Life Science Parkway, Changping District, Beijing, People's Republic of China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and

    1/17/24 6:05:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Financials

    Live finance-specific insights

    View All

    Genetron Health Reports Unaudited First Quarter 2022 Financial Results

    BEIJING, June 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the first quarter ended March 31, 2022. First Quarter and Recent Highlights Recorded total revenue of RMB 110.3 million (US $17.4 million) in the first quarter of 2022, representing 19.8% increase over the same period in 2021. LDT revenue was RMB 81.5 million (US $12.9 million), representing 13.5% increase over the same period in 2021.IVD re

    6/2/22 7:19:58 AM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022

    BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended March 31, 2022 on June 2, 2022 before the US market open. Management will host a conference call for investors at 8:30 a.m. ET (8:30 p.m. Beijing time) on Thursday, June 2, 2022. The conference call can be accessed by dialing the following numbers: United States:+1-833-239-5565China Domestic:400-820-528

    5/23/22 4:05:00 PM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health Announces Unaudited Fourth Quarter and Full Year 2021 Financial Results

    BEIJING, March 29, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2021. 2021 and Recent Business Highlights Therapy Selection: As of December 31, 2021, the Company had 58 hospital partners, of which 30 were IVD hospital partners. Genetron Health is continuing to enhance its in-hospital sales effort.

    3/29/22 7:26:05 AM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Leadership Updates

    Live Leadership Updates

    View All

    Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

    BEIJING, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that the special committee (the "Special Committee") of the Company's Board of Directors (the "Board") has retained Kroll, LLC (operating through its Duff & Phelps Opinions Practice) as its independent financial advisor and Davis Polk & Wardwell LLP as its independent legal counsel. The Special Committee was formed to evaluate and consider the previously announced preliminary

    9/2/22 7:00:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer

    --Closes $5 million Series A financing-- --Appoints Pritesh J. Gandhi, PharmD, as Chief Executive Officer and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations-- --Announces exclusive license of TellDx platform to Genetron Holdings Limited for China-- --Secures Deployment of TellDx at ARUP Laboratories, Inc-- BEVERLY, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection and treatment of cancer through its unique and proprietary circulating tumor cell (CTC) technology, TellDx, and complementary therapeutics platform, TellRx, today announced the closing of a $5 million Series A

    5/10/21 7:00:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)

    4/2/24 5:44:00 PM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)

    4/1/24 4:15:35 PM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)

    3/29/24 8:04:05 AM ET
    $GTH
    Medical Specialities
    Health Care